Joint (NASDAQ:JYNT) Rating Increased to Buy at StockNews.com

Joint (NASDAQ:JYNT) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Friday.

Separately, Roth Mkm lowered their price objective on shares of Joint from $16.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 8th.

Joint Stock Performance

JYNT opened at $11.22 on Friday. Joint has a one year low of $8.29 and a one year high of $17.82. The company has a market cap of $168.08 million, a price-to-earnings ratio of -9.84 and a beta of 1.57. The business’s fifty day moving average is $11.31 and its two-hundred day moving average is $12.96.

Hedge Funds Weigh In On Joint

Several hedge funds have recently bought and sold shares of JYNT. FMR LLC increased its position in Joint by 38.0% during the 3rd quarter. FMR LLC now owns 10,787 shares of the company’s stock worth $123,000 after purchasing an additional 2,971 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Joint during the second quarter worth about $144,000. Sargent Investment Group LLC acquired a new position in shares of Joint in the second quarter valued at approximately $150,000. XTX Topco Ltd purchased a new position in shares of Joint during the second quarter valued at approximately $174,000. Finally, Price T Rowe Associates Inc. MD boosted its position in Joint by 5.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 17,464 shares of the company’s stock worth $229,000 after acquiring an additional 837 shares during the last quarter. Hedge funds and other institutional investors own 76.88% of the company’s stock.

About Joint

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.